DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20175685

Comparative study of adverse effect profile of first line drugs Zidovudine (ZDV) + Lamivudine (3TC) + Nevirapine (NVP) Vs Tenofovir (TDF) + Lamivudine (3TC) + Atazanavir (ATV) + Ritonovir (RTV) in HIV/AIDS patients

Savithri Desai, Sankar Kurli, Harinika G.

Abstract


Background: The biggest threat to mankind from the health perspective is probably the virus Human Immunodeficiency Virus (HIV) responsible for a serious disease known as Acquired Immune Deficiency Syndrome (AIDS). To compare the adverse effect profile of two antiretroviral regimens i.e, Zidovudine (ZDV) + Lamivudine (3TC) + Nevirapine (NVP) [regimen A] Vs Tenofovir (TDF) + Lamivudine (3TC) + Atazanavir(ATV) + Ritonavir (RTV) [regimen B] by clinical and biochemical methods.

Methods: This prospective, observational study was carried out in 200 HIV positive patients receiving first line and second-line antiretroviral therapy (ART) at ART centre, GGH, Vijayawada. Out of 200 patients, 100 patients received regimen A [(ZDV) + (3TC) + (NVP)] and 100 patients were treated with regimen B [(TDF) + (3TC) + (ATV) + (RTV)]. The collected data has been analysed and presented.

Results: Out of 200 patients, 110 patients developed ADRs. In this 110, 38 patients received regimen A and 18 patients received regimen B and had CD4 + count <250 cells/mm3. In the remaining 54 patients, 20 patients received regimen A and 34 patients received regimen B who had CD4+ count >250 cells/ mm3.

Conclusions: The ADRs were most common in those patients whose CD4+ count is less than 250cells/cu mm. Though the patients on second line showed significant increase in CD4+count, number of patients with ADRs were also more with regimen B. Though atazanavir containing regimen is more efficacious than zidovudine containing regimen, but regimen B produces more serious adverse effects. So, second line drugs are reserved for treatment failures to first line, drug resistance and for those not tolerating first line drugs.


Keywords


AIDS, ADRs, HIV, Atazanavir, ART

Full Text:

PDF

References


Fauci AS, Braunwald E, Kasper DL, Hauser SL, Longo DL, Jameson JL, et al. Infectious Diseases. In: Harrison's principles of internal medicine. 17th Ed. McGraw-Hill; 2008:1137-1203.

WHO. Global Health Observatory, 2016. Available at: http://www.who.int/gho/hiv/en/. Accessed 20 June 2017.

WHO. Top 10 causes of death, 2016. Available at: http://www.who.int/mediacentre/factsheets/fs310/en/index.html. Accessed 23 May 2017.

Wikipedia. List of countries by HIV/AIDS prevalence rate, 2012. Available at: http://www.en.wikipedia.org/wiki/List_of_countries_by_HIV/AIDS_adult_prevalence_rate. Accessed 9 June 2012.

Bruton LL, Lazo JS, Parker KL. Goodman & Gilmans: The Pharmacological Basis of Therapeutics. McGraw-Hill; 2008:1273-1310.

Coffin JM. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science-AAAS-Weekly Paper Edition. 1995;267(5197):483-9.

NACO. National guidelines on second line ART for adults and adolescents, 2011. Available at: http://www.medbox.org%2Fnational-guidelines-on-second-line-art-for-adults-and-adolescents-india%2F download.pdf. Accessed 1 April 2011

Palella Jr FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. HIV Outpatient Study Investigators. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. New England J Med. 1998;338(13):853-60.

Li Y, McDonald AM, Dore GJ, Kaldor JM, National HIV Surveillance Committee. Improving survival following AIDS in Australia, 1991–1996. Aids. 2000 Oct 20;14(15):2349-54.

Desai M, Iyer G, Dikshit RK. Antiretroviral drugs: critical issues and recent advances. Indian J pharmacol. 2012;44(3):288.

NACO. Fact sheet: Annual report, 2010-11. Available at: http://www.nacoonline.org/Quick_Links/ Directory_of_HIV_Data. Accessed 10 August 2012.

Bhandarkar PN, Mohd S, Kannan K, Jogdand GS. Sociodemographic Profile of HIV patients at ICTC, CAIMS, Karimnagar. Int J Biol Med Res. 2011;2(4):1023-5.

Agu K, Ochei U, Oparah A, Onoh O. Treatment outcomes in patients receiving combination antiretroviral therapy in central hospital, Benin City, Nigeria. Tropical J Pharma Res. 2010;9(1).

Sungkanuparph S, Manosuth W, Kiertiburanakul S, Piyavong B, Chumpathat N, Chantratita W. Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails. Clinical Infectious Diseases. 2007;44(3):447-52.

Pujades-Rodriguez M, O'brien D, Humblet P, Calmy A. Second-line antiretroviral therapy in resource-limited settings: the experience of Medecins Sans Frontieres. Aids. 2008;22(11):1305-12.

Fox MP, Ive P, Long L, Maskew M, Sanne I. High rates of survival, immune reconstitution, and virologic suppression on second-line antiretroviral therapy in South Africa. JAIDS. 2010;53(4):500-6.

FDA. Approval of Stavudine, 1994. Available at: http://www.fda.gov/bbs/topics/NEWS/NEW00486.html. Accessed 27 June1994.

Ferradini L, Ouk V, Segeral O, Nouhin J, Dulioust A, Hak C, et al. High efficacy of lopinavir/r-based second-line antiretroviral treatment after 24 months of follow up at ESTHER/Calmette Hospital in Phnom Penh, Cambodia. J Int AIDS Soc. 2011;14(1):14.

Hosseinipour MC, Kumwenda JJ, Weigel R, Brown LB, Mzinganjira D, Mhango B, et al. Second‐line treatment in the Malawi antiretroviral programme: high early mortality, but good outcomes in survivors, despite extensive drug resistance at baseline. HIV medicine. 2010;11(8):510-8.

Singh H, Dulhani N, Tiwari P, Singh P, Sinha T. A prospective, observational cohort study to elicit adverse effects of antiretroviral agents in a remote resource-restricted tribal population of Chhattisgarh. Indian J Pharmacol. 2009;41(5):224.

Srikanth BA, Babu SC, Yadav HN, Jain SK. Incidence of adverse drug reactions in human immune deficiency virus-positive patients using highly active antiretroviral therapy. Journal of advanced pharmaceutical technology & research. 2012 Jan;3(1):62.

University of Nairobi. Post Grad Students Projects for the year, 2017. Available at: http://www.uonbi.ac.ke/faculties/postgrad-student-projects-details.php?Project_id=5150&fac_code=61.

Tsiodras S, Mantzoros C, Hammer S, Samore M. Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study. Archives of internal medicine. 2000 Jul 10;160(13):2050-6.

Martínez E, Domingo P, Galindo MJ, Milinkovic A, Arroyo JA, Baldoví F, Larrousse M, León A, de Lazzari E, Gatell JM. Risk of metabolic abnormalities in patients infected with HIV receiving antiretroviral therapy that contains lopinavir-ritonavir. Clinical Infectious Diseases. 2004 Apr 1;38(7):1017-23.

Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, et al. A syndrome of peripheral lipodystrophy, hyperlipidemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 1998;12(7):F51-8.

Graham NM. Metabolic disorders among HIV-infected patients treated with protease inhibitors: a review. Journal of acquired immune deficiency syndromes (1999). 2000;25:S4-11.

Saint-Marc T, Partisani M, Poizot-Martin I, Bruno F, Rouviere O, Lang JM, et al. “A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy.” AIDS. 1999 Sep 10;13(13):1659-67.

Murphy RL, Sanne I, Cahn P, Phanuphak P, Percival L, Kelleher T, et al. Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results. AIDS. 2003;17(18):2603-14.

Gérard L, Chazallon C, Taburet AM, Girard PM, Aboulker JP, Piketty C. Renal function in antiretroviral-experienced patients treated with tenofovir disoproxil fumarate associated with atazanavir/ritonavir. Antiviral therapy. 2007;12(1):31.